Equity
Additional Paid-In Capital
Pfizer Additional Paid-In Capital increased by 0.3% to $94.77B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.0%, from $93.86B to $94.77B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows relatively stable performance with a 1.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase typically reflects equity issuance or stock-based compensation, while a decrease is rare and usually relates to specific accounting adjustments or share cancellations.
Detailed definition
This represents the amount of capital contributed by shareholders in excess of the par value of the stock. It is a key c...
Peer comparison
Standardized equity metric; reflects the company's historical reliance on equity markets for funding growth.
Metric ID:
additional_paid_in_capitalHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $89.34B | $89.97B | $90.59B | $90.84B | $91.18B | $91.36B | $91.80B | $92.15B | $92.33B | $92.50B | $92.63B | $93.00B | $93.20B | $93.48B | $93.60B | $93.86B | $94.05B | $94.25B | $94.47B | $94.77B |
| QoQ Change | — | +0.7% | +0.7% | +0.3% | +0.4% | +0.2% | +0.5% | +0.4% | +0.2% | +0.2% | +0.1% | +0.4% | +0.2% | +0.3% | +0.1% | +0.3% | +0.2% | +0.2% | +0.2% | +0.3% |
| YoY Change | — | — | — | — | +2.1% | +1.5% | +1.3% | +1.4% | +1.3% | +1.2% | +0.9% | +0.9% | +0.9% | +1.1% | +1.0% | +0.9% | +0.9% | +0.8% | +0.9% | +1.0% |
Range$89.34B – $94.77B
CAGR+1.3%
Avg YoY Growth+1.1%
Median YoY Growth+1.0%
Current Streak19+ quarters growth
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Pfizer's additional paid-in capital?
- Pfizer (PFE) reported additional paid-in capital of $94.77B in Q1 2026.
- How has Pfizer's additional paid-in capital changed year-over-year?
- Pfizer's additional paid-in capital increased by 1.0% year-over-year, from $93.86B to $94.77B.
- What is the long-term trend for Pfizer's additional paid-in capital?
- Over 5 years (2020 to 2025), Pfizer's additional paid-in capital has grown at a 1.3% compound annual growth rate (CAGR), from $88.67B to $94.47B.
- What does additional paid-in capital mean?
- The amount of money shareholders paid for stock above its nominal par value.